| Selenium accumulation and metabolism in algae M Schiavon, A Ertani, S Parrasia, F Dalla Vecchia Aquatic Toxicology 189, 1-8, 2017 | 144 | 2017 |
| Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges S Parrasia, I Szabò, M Zoratti, L Biasutto molecular pharmaceutics 19 (11), 3700-3729, 2022 | 38 | 2022 |
| Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1. 3 channel inhibitors by chemical dissection of a novel member of the family R Peruzzo, A Mattarei, M Azzolini, KA Becker-Flegler, M Romio, G Rigoni, ... Redox biology 37, 101705, 2020 | 27 | 2020 |
| Strategies to target bioactive molecules to subcellular compartments. Focus on natural compounds L Biasutto, A Mattarei, M La Spina, M Azzolini, S Parrasia, I Szabo, ... European journal of medicinal chemistry 181, 111557, 2019 | 26 | 2019 |
| Browning effects of a chronic pterostilbene supplementation in mice fed a high-fat diet M La Spina, E Galletta, M Azzolini, S Gomez Zorita, S Parrasia, ... International journal of molecular sciences 20 (21), 5377, 2019 | 21 | 2019 |
| An angiopep2-PAPTP construct overcomes the blood-brain barrier. New perspectives against brain tumors S Parrasia, A Rossa, T Varanita, V Checchetto, R De Lorenzi, M Zoratti, ... Pharmaceuticals 14 (2), 129, 2021 | 13 | 2021 |
| Small-molecule modulators of mitochondrial channels as chemotherapeutic agents S Parrasia, A Mattarei, A Furlan, M Zoratti, L Biasutto CELLULAR PHYSIOLOGY AND BIOCHEMISTRY 53 (S1), 11-43, 2019 | 11 | 2019 |
| Targeting pancreatic ductal adenocarcinoma (pdac) S Parrasia, M Zoratti, I Szabò, L Biasutto Cell Physiol Biochem 55 (1), 61-90, 2021 | 9 | 2021 |
| Multiple mechanisms converging on transcription factor EB activation by the natural phenol pterostilbene M La Spina, M Azzolini, A Salmaso, S Parrasia, E Galletta, M Schiavone, ... Oxidative Medicine and Cellular Longevity 2021 (1), 7658501, 2021 | 7 | 2021 |
| Mitochondrial permeability transition pore: a snapshot of a therapeutic target M Zoratti, L Biasutto, S Parrasia, I Szabo Expert Opinion on Therapeutic Targets 28 (1-2), 1-3, 2024 | 4 | 2024 |
| DA7R: a 7-Letter zip code to target PDAC S Parrasia, A Rossa, N Roncaglia, A Mattarei, C Honisch, I Szabò, ... Pharmaceutics 15 (5), 1508, 2023 | 4 | 2023 |
| 4-Hydroxy-3, 5-Pyridinedicarboxylic Acids: Synthesis, Complexation Properties Towards Fe (III), Al (III), Cu (II), Zn (II), Human Serum Albumin, and Cellular Toxicity A Dean, MG Ferlin, D Carta, T Jakusch, T Kiss, FF Faccioli, S Parrasia, ... Journal of Solution Chemistry 47, 92-106, 2018 | 3 | 2018 |
| Long-Term Pterostilbene Supplementation of a High-Fat Diet Increases Adiponectin Expression in the Subcutaneous White Adipose Tissue S Parrasia, E Galletta, M La Spina, A Magrini, M Azzolini, M Salvalaio, ... Nutraceuticals 2 (2), 102-115, 2022 | 2 | 2022 |
| Corrigendum to “Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1. 3 channel inhibitors by chemical dissection of a novel member of the family … R Peruzzo, A Mattarei, M Azzolini, KA Becker-Flegler, M Romio, G Rigoni, ... Redox Biology 45, 102036, 2021 | 1 | 2021 |
| The novel use of the CFTR corrector C17 in muscular dystrophy: pharmacological profile and in vivo efficacy A Benetollo, S Parrasia, M Scano, L Biasutto, A Rossa, L Nogara, ... Biochemical Pharmacology 233, 116779, 2025 | | 2025 |
| Peptides as a targeting strategy to eradicate Pancreatic Ductal Adenocarcinoma (PDAC) S Parrasia, A Rossa, M Bachmann, V Corbo, A Mattarei, P Ruzza, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1870 (8), 167384, 2024 | | 2024 |
| A novel mertansine conjugate for acid-reversible targeted drug delivery validated through the Avidin-Nucleic-Acid-NanoASsembly platform E Schiavon, S Rezzola, E Filippi, M Turati, S Parrasia, S Bernardotto, ... Nanomedicine: Nanotechnology, Biology and Medicine 62, 102784, 2024 | | 2024 |
| N-palmitoyl-D-glucosamine in a micronized form F Della Valle, MF Della Valle, G Marcolongo, S Parrasia, S Cuzzocrea US Patent 11,744,840, 2023 | | 2023 |
| Pharmacological profile of the most promising CFTR corrector for sarcoglycanopathy treatment. A Benetollo, M Scano, S Parrasia, L Biasutto, FD Barba, P Caccin, ... European Journal of Translational Myology 33 (2), 2023 | | 2023 |
| Composti naturali e loro derivati nella salute e nelle patologie S Parrasia Università degli studi di Padova, 2022 | | 2022 |